INTRODUCTION

Because certain antiganglioside monoclonal antibod-
Effector functions of antitumor monoclonal antibodies can facilitate antibody-dependent cellular cytotoxic-ies (Mabs) include antibody-dependent cellular cytotox-
ity against GD2
/ ganglioside-bearing human and canine icity (ADCC) and complement-dependent cytotoxicity tumor cells, we wished to determine if clinically relevant (CDC) . Both mechanisms are considered relevant for antiganglioside monoclonal antibodies (Mabs) could tumor cell destruction in vitro (1) (2) (3) (4) and in vivo (5) . also fix canine complement to lyse tumor cells in vitro. Some Mabs directed against disialogangliosides GD2 Using flow cytometry, human tumor cell lines (M21 mela-(e.g., Mab 14.G2a, chimeric 14.18) (2, 3) and GD3 (e.g., noma and OHS osteosarcoma) were shown to highly ex-R24, KM641) (1, 6) , antigens expressed on human neupress ganglioside GD2 and, to a lesser degree, GD3. In roblastoma and melanoma cells (7) (8) (9) , are highly effec- tients either alone (6, 12, 13) Mab R24 (against GD3) and canine serum were used. OHS cells were also lysed with canine serum plus Mab We recently described a spontaneous canine mela-14.G2a and lytic activity was abolished by heating ca-noma model in which canine effector cells mediated nine serum but reconstituted with rabbit complement. ADCC of canine melanoma with murine monoclonal Alone, canine serum or Mabs were not lytic to M21 or antiganglioside antibody 14.G2a (IgG2a) specific for OHS cells. Conversely, human neuroblastoma (LAN-5) GD2 or its mouse-human chimera, 14.18, with the and K562 erythroleukemia cells were lysed by canine mouse variable and human constant domains (15) . We serum alone which was shown by flow cytometry to con-determined that human recombinant IL-2 enhanced tain naturally occurring canine IgM antibodies that ADCC of canine melanoma by canine effector cells with bound LAN-5 and K562 cells. The lytic activity of canine these Mabs (15) and human recombinant IL-2 actiserum for LAN-5 or K562 cells was abolished by heating vated the canine immune system in vivo (16) . In the and restored by addition of either human or rabbit com-current report, we sought to examine additional antituplement. Thus, human tumor cell lines can be lysed with mor lytic mechanisms of this canine model of potential antiganglioside Mabs through fixation and activation of importance for human immunotherapy by determining canine complement-dependent lytic pathways. Canine if canine complement could be activated with antiganxenoantibodies also mediate complement-dependent cy-glioside antibodies to lyse ganglioside-expressing tu- Furthermore, while pursuing these investigations of (IgG2a) were obtained commercially (Becton Dickinson, San Jose, CA). canine CDC, we observed that canine serum was naturally cytolytic to some human tumor cell lines. We disDogs. Normal adult male and female mixed breed sected this phenomenon and found that naturally ocdogs and young dogs raised in a research colony served curring canine antibodies of the IgM class mediated as the source of whole blood for serum. All phlebotomy tumor cytotoxicity in conjunction with canine compleprocedures were performed in accordance with a protoment. Thus, natural canine IgM antibodies can funccol approved by the University of Wisconsin Institution as xenoantibodies to lyse human tumor cells in tional Animal Care and Use Committee. conjunction with canine complement.
Taken together, our results indicate that activated Complement. Cold serum, separated from freshly canine complement mediates potent antitumor activity drawn clotted whole blood of healthy dogs or human and this mechanism could be additive with ADCC in a donors, served as the source of canine or human comcanine immunotherapy model targeting tumor ganglio-plement, respectively. Rapidly processed, pooled lyophsides. Our findings that natural canine antibodies bind ilized rabbit serum with complement activity was pursome human tumor lines and react with canine comple-chased commercially (Cappel Research Products, Durment to lyse these cells extend the spectrum of observa-ham, NC). Human blood donations were performed in tions of xenogeneic immunoreactivity of the canine im-accordance with a protocol approved by the Institumune system. These results could also be relevant to tional Review Board of the University of Wisconsin the study of canine xenotransplantation models, which Medical School. are currently receiving considerable attention (17) (18) (19) (20) (21) .
Flow cytometry. Binding of antibodies to live cells was assessed on a FACScan flow cytometer (Becton
MATERIALS AND METHODS
Dickinson) using standard indirect immunofluorescent techniques, as described (15 Cr Monoclonal antibodies. Murine Mab 14.G2a (IgG2a isotype), kindly provided by Dr. Reisfeld and the Na-for 2 hr at 37ЊC in 5% CO 2 atmosphere. These cells were washed in medium and 5 1 10 3 targets in 50 ml tional Cancer Institute (NCI), recognizes disialoganglioside GD2 (3). Its mouse-human chimera, ch 14.18, of supplemented RPMI 1640 were placed into roundbottom microwells. Various concentrations of Mabs constructed of the identical murine variable region, human IgG1 constant region, and k light chains (2), was 14.G2a, ch 14.18, and R24 (also in 50 ml) were added individually to the cell targets and allowed to incubate also a gift from Dr. Reisfeld and the NCI. Murine R24 (IgG3) (24), kindly provided by the NCI, recognizes disi-for 20 min at room temperature. At that time, 100 ml of diluted (1:3) fresh canine, human, or rabbit serum aloganglioside GD3 (25). Monoclonal antibody W3/62 (IgG2a), as hybridoma supernatant (ATCC), was used was added to the wells, resulting in a final 1:6 dilution of serum complement in the microwells. Some wells for detection of major histocompatibility (MHC) class I molecules. Monoclonal antibodies against human MHC received serum which had undergone prior heat inactivation (56ЊC 1 1 hr) while other wells received heatclass II molecules DP (IgG1), DQ (IgG1), and DR inactivated serum plus fresh serum, also at a final concentration of 1:6 for each. The final volume of each well was adjusted to 200 ml with supplemented RPMI 1640 as necessary. All experimental conditions were performed in quadruplicate. Spontaneous and maximum release of 51 Cr from targets was assayed in replicates of eight each. Plates were allowed to incubate for an additional 2 hr at 37ЊC in 5% CO 2 atmosphere. Supernatants were harvested (Skatron, Sterling, VA) at that time and radiolabel released into the supernatant was measured with a gamma counter. The percentage cytotoxicity was calculated using the formula % of cytotoxicity Å Exp cpm 0 Spon cpm Max cpm 0 Spon cpm 1 100,
where Exp was the experimental number of counts from target cells incubated with serum (and antibody), Spon was the spontaneously released counts obtained from targets incubated in medium alone, and Max was the maximum counts obtained from targets lysed with procedure. G2a and R24 resulted in bright fluorescence, blastoma cells with fresh, chilled canine serum, a preindicating high expression of gangliosides GD2 and requisite step for flow cytometric examination, resulted GD3 on these cells (Figs. 1A and 1B) . Expression of in appreciable cell death (determined by flow cytome-GD2 by the M21 line was expected as this cell line was try), precluding cellular analysis. Heat-inactivating capreviously selected by subcloning for strong expression nine serum prior to its incubation with LAN-5 cells did of ganglioside GD2 (2) . not result in cell lysis enabling examination of canine Canine serum, the source of complement in the cy-immunoglobulin binding to LAN-5 cells (Fig. 3) . Both totoxicity assays, was screened for the presence of canine IgG and IgM showed strong binding to these preformed, natural canine antibodies that could react cells (Figs. 3A and 3B ). The LAN-5 line has previously with these human tumor cell targets. Sera from six been shown to express ganglioside GD2 (5). To deterdogs were examined and flow cytometric analyses in-mine if natural canine immunoglobulins bound ganglidicated that binding of canine IgG and IgM to M21 oside GD2, a flow cytometry blocking experiment was cells was nondetectable (IgG) or minimal (IgM) (Figs. performed. LAN-5 cells were initially incubated with 1C and 1D).
RESULTS
heat-inactivated canine serum, washed, and then incubated with ch 14.18, the mouse-human chimera of OHS. Human osteosarcoma OHS cells also stained brightly with Mabs 14.G2a and R24 (Figs. 2A Mab 14.G2a sharing identical reactivity for ganglioside GD2 (2) . This was compared to binding of ch 14.18 to and 2B). Fluorescence intensity and overall distribution of cells positive for Mab 14.G2a were greater LAN-5 cells not preincubated with canine serum (Fig.  3C) . Binding of ch 14.18 was not inhibited by initial than those for R24 indicating ganglioside GD2 ex- and canine serum, human K562 erythroleukemia cells were analyzed for their capacity to bind canine IgG and IgM (Fig. 4) . This cell line was negative for expression of gangliosides GD2 and GD3 as determined by flow incubation of LAN-5 cells with canine serum. These results, repeatable in four separate experiments with cytometry (data not shown). Similar to LAN-5, we found incubation of K562 cells with fresh canine serum sera from four adult dogs, indicated that natural canine immunoglobulin recognized antigenic sites distinct induced considerable cell death prohibiting flow cyto- metric analysis. Heat-inactivated canine serum was not lethal to K562 cells and allowed binding patterns of canine immunoglobulin to K562 to be determined (Fig. 4) . In contrast to LAN-5, canine IgG did not recognize the K562 cells. However, binding of canine IgM to K562 was similar to that observed with the LAN-5 cells. These flow cytometry results were obtained with sera from 5 adult dogs as well as with sera from the same 10 young dogs evaluated against the LAN-5 line. Thus, as with LAN-5, it appears that natural canine antibodies against this human erythroleukemia cell line are present in dogs at an early age. K562 cells were negative for expression of MHC class I and II molecules (data not shown).
Lysis of Tumor Cell Lines Mediated by Canine
Complement and Antiganglioside Mabs 
GD2
/ canine target previously used to demonstrate ca-pressed as mean percentage cytotoxicity {1 SE and are representanine ADCC (15) . However, we did not see tumor killing tive of two separate experiments. The P values indicate significant of the canine CML-10 melanoma target mediated by differences between serum (S) alone and the indicated condition: *P Å 0.0001, #P õ 0.001, Ú P Å 0.03. canine complement or by either rabbit or human complement (not shown). Possible explanations for this included a problem with (canine) complement, a problem stituted by adding rabbit serum (Fig. 5 ). This suggests with antibody, or resistance of the CML-10 cell line to that the component of canine serum responsible for complement-mediated lysis. Thus, we tried other cell tumor lysis with Mab was in fact complement. The cytolines with higher expression of gangliosides as targets. lytic potential of heat-inactivated canine complement We used human tumor cell lines because additional plus R24 was only slightly reconstituted by the addition canine tumor lines expressing gangliosides of interest of rabbit complement. Cytotoxic activity of heat-inactiwere not available.
vated human serum plus R24 also failed to be comThe ganglioside-expressing tumor lines M21 and pletely reconstituted with rabbit complement (not OHS were used as tumor targets. These lines were se-shown), possibly suggesting that there was something lected because of their immunoreactivity with antigan-in heat-inactivated serum competing with the lytic acglioside Mabs 14.G2a and R24, and lack of reactivity tivity of R24 and complement. with natural canine antibodies. In a 2-hr 51 Cr release Similar results were obtained with the OHS osteoassay with the M21 melanoma target, complement-de-sarcoma target using the 14.G2a antibody while the pendent cytotoxicity mediated by complement in ca-cytolytic activity of the R24 and ch 14.18 antibodies nine or rabbit serum, in conjunction with Mabs 14.G2a, plus canine serum as complement source was weak ch 14.18, and R24, was compared (Fig. 5) . Canine se-against this target (Fig. 6) . Lysis of the target was also rum, combined with Mab 14.G2a, ch 14.18, or R24, minimal using rabbit serum plus R24 combined with mediated significant cytotoxicity of M21 cells compared heat inactivated canine serum. The low level of cytotoxto that of canine serum alone. The magnitude of cyto-icity mediated by R24 and complement against this toxicity was comparable to that mediated by rabbit se-target may reflect the lower expression of the target rum with Mab 14.G2a or R24. The combination of ca-GD3 antigen (Fig. 2B) available to bind R24 which was nine serum plus ch 14.18 mediated lower levels of cyto-below the threshold needed to trigger CDC. This could toxicity than rabbit serum plus ch 14.18. This suggests also explain lack of complement-dependent cytotoxicity that canine complement is more effectively activated observed with the canine CML-10 target. for cell lysis by murine monoclonal antibody than by a mouse-human chimeric monoclonal antibody. Heating Lysis of Tumor Cell Lines Mediated by Canine the dog sera, which inactivates the canine complement, Complement and Natural Canine Antibodies abrogated its cytolytic activity when combined with Mabs, and the cytolytic capacity of heat-inactivated caOur flow cytometry results suggested that fresh canine serum killed the LAN-5 neuroblastoma and K562 nine serum (complement) plus Mab 14.G2a was recon-target in a 2-hr 51 Cr release assay (Fig. 8) . In this system, we again found that heating the serum neutralized its lytic properties for tumor cells. As with LAN-5, adding noncytotoxic rabbit complement to heated dog serum restored the serum's tumoricidal effects. These data indicate that heat-labile complement in canine serum was a mediator of tumor cell lysis by canine anti-K562 IgM present in both the fresh and heated serum.
DISCUSSION
We have previously described a canine model for cancer immunotherapy based on ADCC employing tumorreactive antiganglioside Mabs. In the current study, we have extended the utility of this model by demonstrating antitumor properties of canine complement in  FIG. 6 . Lysis of human osteosarcoma (OHS) cells mediated by conjunction with antiganglioside Mabs. Several teams canine complement and monoclonal antiganglioside antibodies. have described the importance of CDC as a mechanism This study has also helped define the requirements for in vitro antitumor CDC in the dog. Binding of C1q erythroleukemia lines. Because canine serum was found to contain natural IgM reactive with both of to the Fc end of antigen-bound antibody initiates the classical complement pathway resulting in tumor cytolthese cell lines and IgG reactive with LAN-5, it was important to determine if the mechanism responsible ysis. Antibody isotypes IgG1, IgG2a, IgG2b, and IgG3 activate this cascade with human complement for cytotoxicity of these lines by canine serum was CDC. In 2-hr 51 Cr release assays, canine serum was (3, 4, 28) , and murine IgG2a and its mouse-human chimera ch 14.18 (human IgG1 Fc end) activate human again lytic to LAN-5 cells (Fig. 7A) . The addition of antiganglioside antibodies did not boost the percentage complement equally well for lysis of M21 cells (2) . Little is known about the requirements for activation of caof cytotoxicity mediated by canine serum alone. On the other hand, rabbit serum or fresh human serum medi-nine complement to lyse tumor cells through the classical pathway. Our results indicate that (murine) antiated only low-level cytotoxicity which was markedly enhanced by the addition of antiganglioside GD2 anti-body isotypes IgG2a and IgG3 are effective triggers of canine complement-mediated tumor cell lysis. Human bodies. Interestingly, heat inactivation of complement activity of canine serum abolished its cytotoxic effect IgG1, on the other hand, is apparently a less potent activator of canine complement for cell lysis as ch against LAN-5 cells. These heat-inactivated canine serum samples had their lytic activity restored by adding 14.18, an antibody with an IgG1 Fc end, mediated only low levels of tumor lysis with canine complement. Howfresh human serum (as a source of complement) (Fig.  7A) . As described in our flow cytometry experiments, ever, because this antibody is a mouse-human chimera, it is possible that canine complement is not actithe binding of canine IgG and IgM to LAN-5 cells was unaffected by prior heating of the serum. Thus, it ap-vated by the human IgG1 Fc end but may potentially be activated by murine IgG1. Species-specific differpears that the lytic activity of canine serum against the LAN-5 line was due to activation of canine comple-ences can account for variability of complement activation with chimeric antibodies (29). One investigator has ment by natural canine immunoglobulin reactive with these tumor cells. Similar results were obtained when suggested that IgG1 can activate canine complement (30) . Additional experiments will need to be done to we used fresh pooled serum from young (i.e., 14-16-week-old) dogs (Fig. 7B) , indicating that canine xeno-answer this question. Finally, although C1q is highly conserved between species (31), the concentration of antibodies against the LAN-5 line are not only present at an early age, but also mediate potent CDC.
hemolytic C1 in normal canine serum is only 20% that of human (30) and appreciably less than that of rabbit Fresh canine serum was also cytolytic for the K562 serum, which might suggest that lower levels of CDC mor responses is unknown. Antibody-dependent cellular cytotoxicity is triggered by relatively few antibody may be mediated by canine complement compared to human or rabbit. Our results indicate this was not the molecules bound to tumor antigen (2) while CDC depends on large amounts of antibody bound to antigen case because the percentage of tumor cell cytotoxicity mediated by canine complement plus some antiganglio-expressed on the tumor surface (28) . Numerous, closely spaced antibody binding sites facilitate close associaside antibodies was comparable to that of rabbit complement plus the same antibodies.
tion of bound complement-fixing antibodies enabling cross-linking of C1q (28) . Thus, CDC might be of greatWhich of the cytolytic mechanisms involving antitumor Mab is more important in achieving in vivo antitu-est clinical significance for the treatment of tumors reactivity with the LAN-5 line and could have contributed to CDC of these cells as well. Thus, while our data show canine natural antibodies react with some xenogeneic tumor lines to trigger CDC, the significance of this finding may relate to analogous reactivity of natural canine antibodies for parenchymal cells of xenotransplants, with delayed organ rejection potentially mediated by CDC directed against the parenchymatous cells proper. Little is known about this possibility in vivo because endothelial cells in the transplant are the first targets to be encountered by natural antibodies in xenotransplants (36) . Binding of natural antibodies to the xenograft endothelium causes hyperacute rejection of the transplanted organ (37) prohibiting evaluation of the effects of natural antibodies and complement on the parenchymal cells of the xenograft. Our results could be germane to these topics in the field of results indicate some of these antibodies are present intensity was weak. Complement-dependent cytotoxicity might also be important in clinical protocols where in healthy dogs from an early age and the epitopes they bind are expressed on some, but not all, human tumor high doses of Mab are administered. This is suggested by a decline in serum complement levels seen only in lines.
Thus, we have shown that canine complement reacts those human patients receiving a high dose ( §30 mg/ m 2 ) of R24 for malignant melanoma (14) or §20 mg/ with several antiganglioside Mabs which are currently in clinical trials for immunotherapy of human cancer. m 2 of Mab 3F8 for treatment of melanoma and neuroblastoma (32) .
These interactions promote appreciable lysis of tumor cells, a mechanism of potential importance for the conPrevious studies of canine CDC have focused on this mechanism's ability to mediate rejection of xenotrans-tinued development of our spontaneous canine malignant melanoma immunotherapy model. Furthermore, planted organs into dogs (18) (19) (20) 33 ). Rejection of xenografts in dogs is mediated by natural preformed canine the demonstration that canine complement and natural antibodies mediated high levels of tumor cell lysis antibodies binding to antigens expressed on transplanted endothelial cells (34) with subsequent activa-in the xenogeneic system provides additional evidence that complement-mediated pathways could offer a tion of canine complement (35) and rapid formation of microthrombi (20). Our study addressed another aspect promising opportunity to exploit for cancer immunotherapy in the dog. of this phenomenon as it relates to tumor rejection and our interest in cancer immunotherapy. The canine xenoantibodies that we identified showed strong binding ACKNOWLEDGMENTS patterns to two human tumor lines, LAN-5 and K562, and were potent activators of the canine complement plement activation (28) . Canine IgG also showed strong
